Table 3.
Summary results ‐ biomarker analyses at 6 months
|
Number of studies |
Number of PCSK9 participants |
Number of comparator arm participants |
Fixed‐effect (95% CI) |
Random‐effects (95% CI) |
Between‐study heterogeneity P value |
|
| Placebo comparison | ||||||
| LDL‐C % change | 8 | 3255 | 1527 | ‐57.62 (‐59.37 to ‐55.87) | ‐53.86 (‐58.64 to ‐49.08) | < 0.001 |
| HDL‐C % change | 5 | 2324 | 1175 | 5.48 (4.37 to 6.59) | 6.00 (4.31 to 7.69) | 0.19 |
| Triglycerides % change | 5 | 2324 | 1175 | ‐14.62 (‐16.74 to ‐12.50) | ‐11.39 (‐17.04 to ‐5.74) | < 0.001 |
| Total cholesterol % change | 2 | 1762 | 895 | ‐35.79 (‐37.36 to ‐34.23) | ‐31.41 (‐43.65 to ‐19.16) | < 0.001 |
| Apolipoprotein A1 % change | 3 | 2043 | 1033 | 3.49 (2.38 to 4.60) | 3.50 (2.37 to 4.64) | 0.36 |
| Apolipoprotein B % change | 6 | 2507 | 1239 | ‐47.79 (‐49.51 to ‐46.08) | ‐41.93 (‐49.76 to ‐34.10) | < 0.001 |
| Lipoprotein(a) % change | 4 | 2252 | 1140 | ‐22.43 (‐24.30 to ‐20.56) | ‐19.80 (‐25.43 to ‐14.17) | < 0.001 |
| Non‐HDL‐C % change | 4 | 2252 | 1140 | ‐50.03 (‐51.73 to ‐48.33) | ‐47.17 (‐53.92 to ‐40.42) | < 0.001 |
| HbA1c absolute change | 2 | 490 | 245 | 0.00 (‐0.04 to 0.05) | 0.01 (‐0.06 to 0.08) | 0.151 |
| Ezetimibe and statin comparison | ||||||
| LDL‐C % change | 5 | 3309 | 2067 | ‐52.17 (‐53.91 to ‐50.43) | ‐39.20 (‐56.15 to ‐22.26) | < 0.001 |
| HDL‐C % change | 3 | 333 | 578 | 7.53 (5.54 to 9.51) | 6.42 (1.31 to 11.52) | 0.002 |
| Triglycerides % change | 2 | 229 | 327 | ‐3.47 (‐8.26 to 1.32) | ‐3.47 (‐8.26 to 1.32) | 0.46 |
| Total cholesterol % change | ||||||
| Apolipoprotein A1 % change | ||||||
| Apolipoprotein B % change | 3 | 333 | 578 | ‐26.86 (‐29.50 to ‐24.22) | ‐26.72 (‐30.26 to ‐23.19) | 0.169 |
| Lipoprotein(a) % change | 2 | 207 | 453 | ‐19.51 (‐24.48 to ‐14.53) | ‐19.51 (‐24.48 to ‐14.53) | 0.60 |
| Non‐HDL‐C % change | 2 | 207 | 453 | ‐28.19 (‐32.79 to ‐23.59) | ‐28.19 (‐32.79 to ‐23.59) | 0.65 |
| HbA1c absolute change | ||||||
| Ezetimibe comparison | ||||||
| LDL‐C % change | 2 | 531 | 292 | ‐30.20 (‐34.18 to ‐26.23) | ‐30.20 (‐34.18 to ‐26.23) | 0.71 |
| HDL‐C % change | 2 | 531 | 292 | 7.40 (5.11 to 9.70) | 7.01 (3.70 to 10.32) | 0.22 |
| Triglycerides % change | 2 | 531 | 292 | ‐0.43 (‐4.90 to 4.03) | ‐0.43 (‐4.90 to 4.03) | 0.89 |
| Total cholesterol % change | 2 | 531 | 292 | ‐15.51 (‐18.18 to ‐12.83) | ‐15.84 (‐19.37 to ‐12.30) | 0.24 |
| Apolipoprotein A1 % change | 2 | 531 | 292 | 6.13 (4.34 to 7.91) | 6.13 (4.34 to 7.91) | 0.68 |
| Apolipoprotein B % change | 2 | 531 | 292 | ‐23.18 (‐26.28 to ‐20.08) | ‐23.18 (‐26.28 to ‐20.08) | 0.37 |
| Lipoprotein(a) % change | 2 | 531 | 292 | ‐18.70 (‐23.03 to ‐14.37) | ‐13.69 (‐30.60 to 3.21) | 0.003 |
| Non‐HDL‐C % change | 2 | 531 | 292 | ‐23.45 (‐27.07 to ‐19.83) | ‐23.45 (‐27.07 to ‐19.83) | 0.57 |
| HbA1c absolute change | ||||||